BioAmber Inc. (BIOA) Receives Hold Rating from Cowen and Company
Cowen and Company reaffirmed their hold rating on shares of BioAmber Inc. (NYSE:BIOA) in a research note published on Friday. Cowen and Company currently has a $1.00 target price on the biotechnology company’s stock.
A number of other research firms have also recently commented on BIOA. HC Wainwright reiterated a buy rating and set a $12.00 price objective on shares of BioAmber in a research report on Wednesday. Zacks Investment Research upgraded BioAmber from a sell rating to a hold rating in a research report on Wednesday, July 26th. Finally, ValuEngine cut BioAmber from a sell rating to a strong sell rating in a research report on Tuesday, August 8th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and one has issued a buy rating to the company’s stock. The stock presently has an average rating of Hold and an average price target of $6.50.
BioAmber (NYSE:BIOA) traded down $0.01 during trading on Friday, reaching $0.43. The company had a trading volume of 1,694,700 shares, compared to its average volume of 941,417. BioAmber has a 1 year low of $0.32 and a 1 year high of $6.50. The company has a debt-to-equity ratio of 0.24, a current ratio of 1.08 and a quick ratio of 1.03.
A number of institutional investors and hedge funds have recently bought and sold shares of the business. FMR LLC grew its holdings in BioAmber by 1.9% in the 2nd quarter. FMR LLC now owns 1,360,000 shares of the biotechnology company’s stock valued at $3,495,000 after buying an additional 25,000 shares during the period. Vanguard Group Inc. grew its holdings in BioAmber by 9.9% in the 2nd quarter. Vanguard Group Inc. now owns 303,360 shares of the biotechnology company’s stock valued at $780,000 after buying an additional 27,278 shares during the period. Bank of New York Mellon Corp grew its holdings in BioAmber by 336.2% in the 2nd quarter. Bank of New York Mellon Corp now owns 54,106 shares of the biotechnology company’s stock valued at $139,000 after buying an additional 41,701 shares during the period. TD Asset Management Inc. purchased a new stake in BioAmber in the 2nd quarter valued at about $977,000. Finally, Robecosam AG grew its holdings in BioAmber by 82.9% in the 3rd quarter. Robecosam AG now owns 1,478,000 shares of the biotechnology company’s stock valued at $741,000 after buying an additional 670,000 shares during the period. Institutional investors own 36.28% of the company’s stock.
BioAmber Company Profile
BioAmber Inc (BioAmber), formerly DNP Green Technology, Inc, is an industrial biotechnology company, which produces sustainable chemicals. The Company’s technology platform combines industrial biotechnology and chemical catalysis to convert renewable feedstocks into sustainable chemicals that are replacements for petroleum-derived chemicals, which are used in a range of everyday products, including plastics, food additives and personal care products.
Receive News & Stock Ratings for BioAmber Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioAmber Inc. and related stocks with our FREE daily email newsletter.